Search tips
Search criteria 


Logo of bmjcrInstructions for authorsCurrent ToCBMJ Case Reports
BMJ Case Rep. 2010; 2010: bcr09.2009.2243.
Published online 2010 January 13. doi:  10.1136/bcr.09.2009.2243
PMCID: PMC3028224
Unexpected outcome (positive or negative) including adverse drug reactions
Catastrophic cerebral antiphospholipid syndrome presenting as cerebral infarction with haemorrhagic transformation after sudden withdrawal of warfarin in a patient with primary antiphospholipid syndrome
Abdul Majid Wani,1 Waleed Mohd Hussain,2 Mousa Ali Al Mejally,3 Khaled Shawkat Ali,4 Sadeya Hanif Raja,2 Wael Al Maimani,5 Mazen G Bafaraj,4 Ashraf Bashraheel,4 Mubeena Akhtar,2 and Amer Mohd Khoujah6
1Hera General Hospital, Medicine, 4a/201, Makkah, Western, 21955, Saudi Arabia
2Hera General Hospital, Medicine, Makkah, Western, 21955, Saudi Arabia
3Hera General Hospital, Medicine, Makka-KSA, Makkah, PO Box 20993, Saudi Arabia
4Hera General Hospital, Makkah, 21955, Saudi Arabia
5Umm Al-Qura University, Makkah, 21955, Saudi Arabia
6National Guard Hospital, Medicine, Jeddha, Western, 21955, Saudi Arabia
Abdul Majid Wani, dr_wani_majid/at/
Catastrophic antiphospholipid syndrome (APS) is caused by thrombotic vascular occlusions that affect both small and large vessels, producing ischaemia in the affected organs. The “catastrophic” variant of the antiphospholipid syndrome (cAPS) develops over a short period of time. Although patients with cAPS represent <1% of all patients with APS, they are usually life threatening with a 50% mortality rate. A strong association with concomitant infection is thought to act as the main trigger of microthromboses in cAPS. Several theories have been proposed to explain these physiopathological features. Some of them suggest the possibility of molecular mimicry between components of infectious microorganisms and natural anticoagulants, which might be involved in the production of cross-reacting antiphospholipid antibodies. We present a case of catastrophic cerebral APS characterised by massive temporal lobe infarction and subsequent haemorrhagic transformation after sudden withdrawal of warfarin.
We report this case to highlight the importance of anticoagulation in antiphospholipid syndrome; to highlight the risks of sudden discontinuation of warfarin; and to describe the cerebral catastrophic antiphospholipid syndrome and the need for early recognition.
This case involved an 18-year-old Saudi female with primary antiphospholipid syndrome, who had been receiving treatment with warfarin for the previous 3 months for cerebral venous thrombosis and inferior vena caval thrombosis, and was doing well with a target international normalised ratio (INR) of 3–3.5. The patient presented with lower cranial nerve palsy, hydrocephalous and aseptic meningitis, all of which had improved clinically and radiologically. The anticardiolipin antibodies (IgM and IgG) were positive in high titre on admission to hospital and 12 weeks later. Ten days earlier the patient stopped her warfarin medication due to its non-availability in a remote area. Two days later the patient developed headache which progressed to altered sensorium within another 3 days. The patient was brought to the hospital and an examination in the emergency room revealed her to be in a confused state with respiratory distress. A computed tomography (CT) scan revealed extensive right temporal lobe haemorrhage with areas of normal looking brain tissue, cerebral oedema and gross midline shift (figs 1 and and2).2). There was ventricular extension of the haemorrhage. A chest x-ray was normal, but haemoglobin was only 10.0 g/dl. D-dimer values were increased and fibrinogen value decreased. Anticardiolipin antibodies were again positive with IgM almost double the normal titre and IgG above normal. The patient was admitted to intensive care and put on a mechanical ventilator. Decongestant therapy with mannitol was started and a neurosurgical consultation sought. Brainstem reflexes were absent and an electroencephalogram (EEG) revealed no activity, and patient was declared brain dead.
Figure 1
Figure 1
Computed tomography (CT) scan of the brain showing temporal lobe haemorrhagic transformation of the infarct.
Figure 2
Figure 2
CT scan of the brain showing classical haemorrhagic transformation of the infarct with areas of normal looking brain tissue, ventricular extension of blood, midline shift and cerebral oedema.
Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterised by a combination of arterial or venous thrombosis and recurrent fetal loss, accompanied by elevated titres of antiphospholipid antibodies (aPL). Catastrophic antiphospholipid syndrome (cAPS) or Asherson’s syndrome is a small subset of accelerated APS characterised by widespread systemic thrombotic disease with multiorgan failure.1 Cerebral involvement is seen in 60% of cases of cAPS2 in some studies, and 72% of cases have been female with a mean age of 37±14 years (range 11–60 years). The organ systems most commonly involved at the onset include the cardiopulmonary system, primarily characterised by dyspnoea and respiratory failure, the central nervous system, and the renal system. The pathogenesis of catastrophic APS is not completely understood. Growing evidence suggests it is a unique condition. This statement is based on several clinical and physiopathological features that, although not well understood, define cAPS by itself. The remarkable features of cAPS are the presence of antiphospholipid antibodies (aPLAs) and microthromboses. Additional physiopathological features are the presence of anaemia and thrombocytopenia, which are also often described in similar autoimmune conditions. A strong association with concomitant infection is thought to act as the main trigger of microthromboses in cAPS. Several theories have been proposed to explain these physiopathological features. Some of them suggest the possibility of molecular mimicry between components of infectious microorganisms and natural anticoagulants, which might be involved in the production of cross-reacting aPLAs in cAPS. Some genetic risk factors have also been suggested as being implicated in the onset of cAPS, although they have not been defined yet.3 The mortality rate was 50% in the earliest published series, but recently it has clearly fallen by some 20% due to the use, as first line treatments, of full anticoagulation, corticosteroids, plasma exchanges, and intravenous immunoglobulins. Cerebral involvement has been identified as the main cause of death, being present in one third of patients, and consisting mainly of stroke, cerebral haemorrhage and encephalopathy, followed by cardiac involvement and infection.4
cAPS in the central nervous system has been reported as an isolated event.5 Status epileptics has been reported as the presentation of cAPS in purpurium,6 as has been hemispheric infarction.1 Our case had a massive temporal lobe infarct with haemorrhagic transformation and severe brain oedema and midline shift. The likely event in our case was transverse sinus thrombosis with involvement of feeding temporal lobe veins. This is well explained by venous drainage of the temporal lobe.7
There are criteria proposed for the diagnosis of cAPS, mainly for epidemiological purposes.8 The precipitating factors for cAPS so far reported in the literature are trauma, surgery, infection, drugs such as oral contraceptives, pregnancy, purpurium, malignancy, and warfarin withdrawal.9,10 Sudden withdrawal of warfarin causing cAPS has been reported in two cases so far.9 Splenic infarction has been reported after warfarin discontinuation in a patient with atrial fibrillation.11 This is attributed to transient rebound hypercoagulability due to increased synthesis of fibrin and thrombin.12 Some cases occur due to antithrombin antibodies and a sudden rise in factor VII.
Patients with APS need to be educated about the importance of complying with their anticoagulation medication. They also need to have ready access to an anticoagulation clinic to monitor their INR in order to prevent cAPS, which has a high mortality rate despite aggressive anticoagulation, corticosteroids, plasmapheresis and/or immunoglobulins.
Learning points
  • Catastrophic antiphospholipid syndrome (APS) with high mortality may result from sudden withdrawal of warfarin in patients with APS.
  • Patients with APS must be educated about the importance of compliance with their anticoagulant medication and should be regularly followed for target INR.
  • Greater vigilance is needed in APS patients during states of stress such as pregnancy, puerpurium, surgery and infections.
  • Catastrophic APS must be suspected in cases exhibiting a rapid deterioration of level of consciousness.
We acknowledge the support provided by our director postgraduate education and training Mrs. Manal Karima and secretary Miss Mecciya Hadi Al Marjoshi.
Competing interests: None.
Patient consent: Patient/guardian consent was obtained for publication.
1. Modrykamien A, Reddy A, Guzman JA, et al. Massive cerebrovascular infarct due to the catastrophic antiphospholipid syndrome in a patient with idiopathic thrombocytopenic purpura. J Intensive Care Med 2009; 24: 269–72. [PubMed]
2. Cervera R, Bucciarelli S, Plasín MA, et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the “CAPS Registry”. J Autoimmun 2009; 32: 240–5. [PubMed]
3. Ortega-Hernandez OD, Agmon-Levin N, Blank M, et al. The physiopathology of the catastrophic antiphospholipid (Asherson’s) syndrome: compelling evidence. Autoimmun 2009; 32: 1–6. [PubMed]
4. Espinosa G, Bucciarelli S, Asherson RA, et al. Morbidity and mortality in the catastrophic antiphospholipid syndrome: pathophysiology, causes of death, and prognostic factors. Semin Thromb Hemost 2008; 34: 290–4. [PubMed]
5. Huang MN, Hsieh SC. Catastrophic antiphospholipid syndrome in the central nervous system. J Rheumatol 2009; 36: 651. [PubMed]
6. Coward LJ, Kullmann DM, Hirsch NP, et al. Catastrophic primary antiphospholipid syndrome presenting as status epilepticus. J Neurol Neurosurg Psychiatry 2005; 76: 1607–8. [PMC free article] [PubMed]
7. Miabi Z, Midia R, Rohrer SE, et al. Delineation of lateral tentorial sinus with contrast-enhanced mr imaging and its surgical implications. Am J Neuroradiol 2004; 25: 1181–8. [PubMed]
8. Asherson RA, Cervera R, de Groot PG. Catastrophic antiphospholipid syndrome: International consensus statement on classification criteria and treatment guidelines. Lupus 2003; 12: 530–4. [PubMed]
9. Erkan D, Yazici Y, Peterson MG, et al. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology 2002; 41: 924–9. [PubMed]
10. Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore) 1998; 77: 195–207. [PubMed]
11. Trappolini M, Scorzai A, Loguercio V, et al. Splenic infarction after warfarin discontinuation during atrial fibrillation. Clin Ter 2008; 159: 435–7. [PubMed]
12. Genewein U, Haeberli A, Straub PW, et al. Rebound after cessation of oral anticoagulant therapy: the biochemical evidence. Br J Haematol 1996; 92: 479–85. [PubMed]
Articles from BMJ Case Reports are provided here courtesy of
BMJ Group